Sunday 18 October 2026
Export RLMD’s income statement to Excel — free account
Relmada Therapeutics, Inc.
RLMD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.3% and free cash flow fell 50.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.10
0.10
−3.13%
Follow RLMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
29.52 | 18.26 | 14.62 | 2.86 |
+8 more quarters Free account |
Net Debt/EBITDA |
14.50 | 12.02 | 4.57 | 1.34 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.79 | 0.73 | 0.67 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.09) | (0.17) | (0.37) | (0.20) | |
Cash per Share |
1.94 | 2.70 | 2.36 | 0.42 | |
Shareholders Equity per Share |
1.84 | 2.53 | 2.19 | 0.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.84 | 2.53 | 2.19 | 0.29 | |
Free Cash Flow |
(9.61) | (15.07) | (14.60) | (6.72) | |
Working Capital |
211.62 | 222.45 | 87.55 | 9.66 | |
Net Current Asset Value |
206.54 | 218.71 | 86.49 | 9.44 | |
| Other line items | |||||
Quick Ratio |
29.34 | 18.15 | 14.46 | 2.68 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.09) | (0.17) | (0.37) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.05 | — | — | — | |
Average Payables |
1.89 | 3.50 | 2.85 | 1.90 | |
Average Assets |
120.09 | 131.52 | 69.91 | 35.30 | |
Average Common Equity |
111.25 | 120.59 | 61.02 | 28.55 |
Columns are period end dates